TAMPA, Fla. & WORCESTER, Mass.--(BUSINESS WIRE)--May 10, 2006--A majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI - News), Biovest International, Inc. (OTCBB:BVTI - News), has been informed by the United States Food and Drug Administration (FDA) that its patent-pending AutovaxID(TM) device requires no further review by the FDA, allowing Biovest to commence commercialization of the device. AutovaxID is, to the best of the Company’s knowledge, the first and only instrument to enable the cost-effective and scalable production of cells or cell-derived products such as monoclonal antibodies for personalized medicine applications. Potential applications include production of vaccines to treat a variety of diseases, as well as stem-cell amplification for therapeutic uses. AutovaxID is a reusable device that hosts a companion single-use, disposable, closed-system chamber containing a hollow-fiber cell-growth cartridge. This unique instrument has the potential to replace conventional cell-growth chambers that require up to ten times as much laboratory space, as well as additional labor and increased expenses.
